Stoke Therapeutics Utdelningar och återköp

Utdelning kriterier kontrolleras 0/6

Stoke Therapeutics har inte registrerat sig för att betala utdelning.

Viktig information

n/a

Avkastning på utdelning

-8.9%

Återköpsavkastning

Total avkastning till aktieägarna	-8.9%
Framtida utdelningsavkastning	n/a
Utdelningstillväxt	n/a
Nästa utbetalningsdag för utdelning	n/a
Ex utdelningsdag	n/a
Utdelning per aktie	n/a
Utdelningsandel	n/a

Senaste utdelnings- och återköpsuppdateringar

Inga uppdateringar

Recent updates

Seeking Alpha • 13h

Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results

As you might know, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just kicked off its latest quarterly results with some very...

Ny berättelse • May 11

Phase III Trial And Payer Risks Will Shape Dravet Treatment Prospects

Catalysts About Stoke Therapeutics Stoke Therapeutics is a biotechnology company focused on RNA-based medicines, including zorevunersen for Dravet syndrome. What are the underlying business or industry changes driving this perspective?

Analysartikel • Jan 12

Newsflash: Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Have Been Trimming Their Revenue Forecasts

The analysts covering Stoke Therapeutics, Inc. ( NASDAQ:STOK ) delivered a dose of negativity to shareholders today, by...

Analysartikel • Dec 05

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 36% But Its Business Still Trails The Industry

Despite an already strong run, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have been powering on, with a gain of...

Analysartikel • Oct 09

Stoke Therapeutics, Inc. (NASDAQ:STOK) Held Back By Insufficient Growth Even After Shares Climb 39%

Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have continued their recent momentum with a 39% gain in the last month...

Analysartikel • Aug 25

Improved Revenues Required Before Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock's 49% Jump Looks Justified

Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have continued their recent momentum with a 49% gain in the last month...

Analysartikel • Aug 15

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Could Be 25% Above Their Intrinsic Value Estimate

NasdaqGS:STOK 1 Year Share Price vs Fair Value Explore Stoke Therapeutics's Fair Values from the Community and select...

Analysartikel • May 20

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 28% But Its Business Still Trails The Industry

Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders would be excited to see that the share price has had a great...

Analysartikel • Apr 16

Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be

Market forces rained on the parade of Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders today, when the analysts...

Analysartikel • Apr 05

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

To the annoyance of some shareholders, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares are down a considerable 27% in...

Analysartikel • Feb 26

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Feb 16

Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer

Summary Stoke Therapeutics' RNA-based treatments for severe neurological and ophthalmic disorders, particularly zorevunersen for Dravet syndrome, show potential for long-term value beyond a single drug. Financials reveal high R&D spending and cash burn, but revenue growth from Acadia Pharmaceuticals collaboration suggests early monetization and potential non-dilutive funding. The Phase 3 EMPEROR study for zorevunersen is critical, with regulatory alignment and promising early data, but execution and long-term safety monitoring remain challenges. Stoke's broader pipeline, including treatments for SYNGAP1-related disorders, Rett syndrome, and Autosomal Dominant Optic Atrophy, could expand its market potential if RNA modulation proves broadly effective. Read the full article on Seeking Alpha

Analysartikel • Nov 08

Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts

Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just released its third-quarter report and things are looking bullish. Results...

Analysartikel • Nov 06

Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts

Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders will have a reason to smile today, with the analysts making...

Stabilitet och tillväxt i betalningar

Hämta utdelningsdata

Stabil utdelning: Otillräcklig data för att avgöra om STOK s utdelningar per aktie har varit stabila tidigare.

Växande utdelning: Otillräcklig data för att avgöra om STOK s utdelningsbetalningar har ökat.

Utdelningsavkastning jämfört med marknaden

Stoke Therapeutics Utdelningsavkastning jämfört med marknaden

Hur är STOK:s direktavkastning jämfört med marknaden?
Segment	Utdelningsavkastning
Företag (STOK)	n/a
Marknadens lägsta 25% (US)	1.3%
Marknad Topp 25% (US)	4.0%
Genomsnitt för branschen (Biotechs)	2.0%
Prognosanalytiker (STOK) (upp till 3 år)	n/a

Anmärkningsvärd utdelning: Det går inte att utvärdera STOK s utdelningsavkastning mot de lägsta 25 % av utdelningsbetalarna, eftersom företaget inte har rapporterat några senaste utbetalningar.

Hög utdelning: Det går inte att utvärdera STOK s utdelningsavkastning mot de översta 25 % av utdelningsbetalarna, eftersom företaget inte har rapporterat några senaste utbetalningar.

Vinstutdelning till aktieägarna

Resultattäckning: Otillräcklig data för att beräkna STOK s utbetalningskvot för att avgöra om dess utdelningar täcks av intäkter.

Kontantutbetalning till aktieägarna

Kassaflödestäckning: Det går inte att beräkna hållbarheten för utdelningar eftersom STOK inte har rapporterat några utbetalningar.

Upptäck bolag med stark utdelning

Företagsanalys och finansiella data Status

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/08/05 02:24
Aktiekurs vid dagens slut	2026/08/05 00:00
Intäkter	2026/06/30
Årlig intjäning	2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

^* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Stoke Therapeutics, Inc. bevakas av 22 analytiker. 11 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

Analytiker	Institution
Gregory Harrison	BofA Global Research
Thomas Shrader	BTIG
Michelle Gilson	Canaccord Genuity

Stoke Therapeutics Utdelningar och återköp

Utdelning kriterier kontrolleras 0/6

Viktig information

Senaste utdelnings- och återköpsuppdateringar

Recent updates

Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement

Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

Stoke Therapeutics, Inc. to Report Q2, 2026 Results on Aug 03, 2026

Stoke Therapeutics Names Thomas McCauley Chief Scientific Officer to Lead RNA Program

Stoke Therapeutics Announces Appointment of Thomas McCauley as Chief Scientific Officer

STOK: Phase 3 Dravet Data And NDA Timeline Will Drive Upside

Stoke Therapeutics Completes EMPEROR Phase 3 Enrollment for Dravet Syndrome Program

Stoke Therapeutics Completes Enrollment Of 162 Patients Into The Phase 3 EMPEROR Study Of Zorevunersen

Stoke Therapeutics, Inc.(NasdaqGS:STOK) dropped from Russell Microcap Index

None

Stoke Therapeutics Advances Zorevunersen With Positive Data and Phase 3 Timeline Update

Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results

First quarter 2026 earnings: EPS and revenues exceed analyst expectations

Phase III Trial And Payer Risks Will Shape Dravet Treatment Prospects

Stoke Therapeutics, Inc., Annual General Meeting, Jun 03, 2026

Stoke Therapeutics, Inc. Appoints Clare Kahn as Directors and to Serve on Nominating and Corporate Governance Committee and as Chairperson of the Research and Development Committee of the Board, Effective April 3, 2026

Chief Medical Officer recently sold US$413k worth of stock

Price target increased by 8.2% to US$45.10

Full year 2025 earnings: EPS and revenues miss analyst expectations

Stoke Therapeutics and Biogen Announce Data Publication for Zorevunersen in Dravet Syndrome

Consensus EPS estimates increase by 79%

Stoke Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of STK-002

Price target increased by 13% to US$41.89

Price target increased by 8.2% to US$39.63

Investor sentiment deteriorates as stock falls 16%

Price target increased by 8.4% to US$37.13

Newsflash: Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Have Been Trimming Their Revenue Forecasts

Stoke Therapeutics, Inc. Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

Consensus EPS estimates increase by 10%

Price target increased by 13% to US$36.63

Price target increased by 8.3% to US$34.25

Advisor & Director exercised options and sold US$467k worth of stock

Stoke Therapeutics, Inc. and Biogen Inc. Present Data That Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 36% But Its Business Still Trails The Industry

Investor sentiment improves as stock rises 15%

Stoke Therapeutics, Inc. and Biogen Inc. Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome

Price target increased by 9.4% to US$30.89

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 21%

Stoke Therapeutics, Inc. Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)

New minor risk - Share price stability

Price target increased by 11% to US$27.00

Stoke Therapeutics, Inc. and Biogen Inc. Present New Data at the 54th Child Neurology Society Annual Meeting That Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

Stoke Therapeutics, Inc. (NASDAQ:STOK) Held Back By Insufficient Growth Even After Shares Climb 39%

Price target increased by 10% to US$25.56

Investor sentiment improves as stock rises 16%

Stoke Therapeutics, Inc. Appoints Ian F. Smith as Chief Executive Officer

Advisor & Director notifies of intention to sell stock

Investor sentiment improves as stock rises 22%

Stoke Therapeutics, Inc. and Biogen Inc. Present Data At the 36Th International Epilepsy Congress That Support the Potential for Zorevunersen to Be the First Disease-Modifying Medicine for Dravet Syndrome

Advisor & Director notifies of intention to sell stock

Improved Revenues Required Before Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock's 49% Jump Looks Justified

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Advisor & Director recently sold US$221k worth of stock

Investor sentiment improves as stock rises 37%

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Could Be 25% Above Their Intrinsic Value Estimate

Now 23% overvalued after recent price rise

Stoke Therapeutics, Inc. and Biogen Inc. Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, A Potential Disease-Modifying Treatment for Dravet Syndrome

Consensus EPS estimates increase by 14%

Investor sentiment improves as stock rises 15%

Stoke Therapeutics, Inc. and Biogen Inc. Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet Syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

Consensus EPS estimates fall by 26%

Investor sentiment improves as stock rises 19%

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 28% But Its Business Still Trails The Industry

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Stoke Therapeutics, Inc., Annual General Meeting, Jun 03, 2025

Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be

Consensus revenue estimates decrease by 11%

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Consensus revenue estimates increase by 70%

Advisor & Director recently sold US$164k worth of stock

Stoke Therapeutics, Inc. Announces CEO Changes, Effective March 19, 2025

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Stoke Therapeutics, Inc. Appoints Arthur Tzianabos as Interim Executive Chairman

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely